Acumen Pharmaceuticals to Present Data on Enhanced Brain Delivery™ (EBD™) Technology and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026
Acumen Pharmaceuticals will present three studies at the Alzheimer’s Association International Conference (AAIC) 2026 in London, including one oral and two poster presentations. The oral presentation details preclinical data on bispecific antibodies using Enhanced Brain Delivery (EBD) technology in cynomolgus monkeys, developed in collaboration with JCR Pharmaceuticals.
Key figures
- Drug Name
- sabirnetug (ACU193)
- Phase Of Trial
- Phase 2
- Trial name
- ALTITUDE-AD
- Trial enrollment
- 542
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.